TrovaGene Inc (NASDAQ: TROV) said it would present clinical data on its precision cancer monitoring platform at the Molecular DX Europe conference, its new press statement said. The company said its presentation was named as "Dynamic Changes in EGFR Mutation Circulating Tumor DNA in Urine on Anti-EGFR Therapy" and will feature data from clinical trials in lung cancer.
According to the company, the presentation will be made by Hatim Husain, who is M.D., University of California, San Diego Moores Cancer Center. The presentation's highlights included Monitoring "early drug response to anti-EGFR therapy to model tumor lysis, analyzing pretreatment kinetis and dynamic changes in circulating tumor DNA" for patients on therapies directed against KRAS.
Aside from that, TrovaGene indicated it would also feature the evaluation of urine as a modality for monitoring ctDNA.
On Wednesday, the stock finished with a gain of 6.37 percent to $5.18.
See more from Benzinga
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.